Effects of Vitamin D and Calcium Supplementation on Inflammatory Biomarkers and Adypocytokines in Diabetic Patients
Information source: Isfahan University of Medical Sciences
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Nutritional and Metabolic Disease
Intervention: vitamin D3 supplement (Dietary Supplement); calcium supplement (Dietary Supplement); vitamin D3 and calcium supplement (Dietary Supplement); placebo (Dietary Supplement)
Phase: N/A
Status: Recruiting
Sponsored by: Isfahan University of Medical Sciences Overall contact: marjan tabesh, MS, Phone: 00989131664159, Email: tabesh@hlth.mui.ac.ir
Summary
The epidemic of type 2 diabetes is an enormous public health problem in all parts of the
world, with 366 million cases by 2030. Chronic inflammation has been postulated to play a
role in the pathogenesis of type 2 diabetes. High levels of adiponectin and inflammatory
biomarkers are known as a new risk factor for diabetes. There is accumulating evidence
suggesting that altered vitamin D and calcium homeostasis affect the development of type 2
diabetes, but it is still unclear whether that effects are through reducing the level of
adipocytokines and inflammatory biomarkers or not. This study has been designed to evaluate
the effects of vitamin D and calcium supplementations alone and in combination on
inflammatory biomarkers and adypocytokines in type 2 diabetic patients.
This study is a single masked, controlled randomized trial with period of 8 weeks. 120
diabetic patients who met the inclusion criteria will enroll in this study. Subjects will
randomly assign in to four groups. Randomization will be achieved by permuted blocks with
stratification by age, sex, BMI, type of diabetes and dose of medication. Group1 will
receive 50000 IU of vitamin D3 per week plus calcium placebo, group2 will received 1000 mg
of calcium carbonate per day plus vitamin D placebo, group 3 will receive 50000 IU of
vitamin D3 plus 100 of mg calcium carbonate per day and group four will receive calcium and
vitamin D placebos. Total cholesterol, HDL, LDL, serum triglyceride, serum glucose, serum
insulin, HbA1C, leptin, adiponectin and inflammatory biomarkers such as TNF-alpha, IL-6 and
high sensitivity C reactive protein (hs-CRP) will be determine by taking blood samples at
the baseline and at the end of intervention. Systolic and diastolic blood pressure and
anthropometric measurements (height, weight, hip and waist circumferences) will be measured
at the baseline and after 8 weeks of intervention. 3 dietary records and 3 physical activity
records will be taken at 2,4 and 6 week of intervention to make sure that all subjects
maintain their usual diet and physical activity during intervention.
Clinical Details
Official title: Effects of Vitamin D and Calcium Supplementation on Inflammatory Biomarkers and Adypocytokines in Diabetic Patients
Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment
Primary outcome: change in inflammatory biomarkers from baseline at 8 weekschange in adipocytokines from baseline at 8 weeks
Secondary outcome: change in weight (Kg) from baseline at 8 weekschange in lipid profile from baseline at 8 weeks change in serum Glucose from baseline at 8 weeks change in height (Cms) from baseline at 8 weeks change in hip circumference (Cms) from baseline at 8 weeks change in waist circumference (Cms) from baseline at 8 weeks change in serum Insulin from baseline at 8 weeks change in HbA1C from baseline at 8 weeks change in blood pressure from baseline at 8 weeks
Eligibility
Minimum age: 30 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- more than 30 years old
- have no history of renal failure, cancer, liver diseases, thyroid diseases or any
other inflammatory diseases
- have no allergy
- do not use any tobacco products
- not using corticosteroids
- not consuming any kinds of vitamin D or calcium supplement
- have not more than 4 kilograms weight change during last 3 months
Exclusion Criteria:
- pregnancy
- insulin dependent diabetes
Locations and Contacts
marjan tabesh, MS, Phone: 00989131664159, Email: tabesh@hlth.mui.ac.ir
Medical School of Isfahan, Isfahan, Iran, Islamic Republic of; Recruiting esmaillzadeh, PhD, Email: esmaillzadeh@hlth.mui.ac.ir marjan tabesh, MS, Principal Investigator
Additional Information
Starting date: February 2012
Last updated: August 10, 2012
|